Trial Profile
Use of Lenalidomide (Revlimid®) in Combination With Dexamethasone in Untreated Non-transplantable Multiple Myeloma in Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 08 Jun 2023 Status changed from active, no longer recruiting to completed.
- 16 May 2022 Planned End Date changed from 30 Dec 2021 to 31 Aug 2022.
- 16 May 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Aug 2022.